ASX:MSB AMEX:GLV AMEX:MAG NYSE:MMC NYSE:MMI NYSE:FND NYSE:TPC NASDAQ:PAA NYSE:PNR AMEX:USL
Momentum leading shares are the market's best performers today. They are the fastest-growing shares on the ASX over the last 90 days. These companies can't get to be leaders without first appearing on our Launch Pad list.
The Launch Pad List is published...
Off topic but as an leading indicator for "market timing" is when defensive stocks return to their original strongest demand zones from their origins of a past move & are met again for another strong rally, this seems it could to be happening to MBS, time will tell!
With that said overall markets could be nearing their record highs and potentially pullback...
MSB has been consolidating until recently when it spiked higher and pulling back currently. This could be a buying opportunity as long as its 50SMA support holds. I will be watching price action at the current levels and targeting the upper Resistance level of $2.95 with a tight stoploss below the swing low or the 50SMA at $1.80.
Please note these are my own...
Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure
results from the landmark DREAM-HF randomized controlled Phase 3 trial in 537 treated patients with chronic heart failure with reduced left ventricular ejection fraction (HFrEF) who received rexlemestrocel-L...
Looks like price is respecting trendline / uptrend.
Price is within range. Needs to break above resistance and stay above for bullish confirmation.
Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stocks).
Overall lots of bullish news, Novartis partnership + FDA Fast...
1. Price has plummeted down and stopped at exact upward sloping 50 Months Moving Average
2. Price got support exactly on the 200 Weeks Moving Average
3. Price got support at a very strong Monthly Support Level
I believe this is a great medium to long term buying buying opportunity, as price got supported at many confluence levels, as this might be a Higher Low on...
I hope you find my analysis useful.
From what I can see, price seems to be holding within the trend channel (bullish sign)
The moving averages are beginning to cross, and as you can see in the past, when that occurred, price rose (bullish sign).
Price needs to hold above the lower trend channel and break past the .786 fib to confirm bullish price...
volatile stock.
playing in stemcell and also covid.
has a bit of a following, potentially could moon.
divergance now showing, the yellow lines are all fib targets.
could be a long shot, Fundamentals are also good.
I found this pattern at tickeron website with the following data:
STATUS = Confirmed
CURRENT CONFIDENCE = 71%
TARGET (EXIT) PRICE = 11.21 USD
BREAKOUT (ENTRY) PRICE = 11.94 USD
DISTANCE TO TARGET PRICE = 6.57%
EMERGED ON = Oct 12, 08:00 AM (EDT)
CONFIRMED ON = Oct 12, 11:59 AM (EDT)
WITH CONFIDENCE LEVEL = 85%
The Descending Triangle pattern has a horizontal...
I hope you like my analysis. Very risky stock to invest in, but with potentially big upside in the scenario that there is good news from the FDA in future, which could conclude with a 3-4month Phase 4 trial (CRL) and see the price action head towards 8.60$, after breaking through previous resistances and fib-levels on the way ... this is in order to respect the...
MSB hit hard down more than 40% in today's opening
Share prices have gapped down and could be heading towards its previous lows at 3.00. This could be a buying opportunity if it holds around the 3.00 mark. It also falls within the long term price channel
Share prices have bounced off at the bottom of the 30 minutes price channel at 5.00 and could head back up to retest critical levels at around 5.20, 5.40, and 5.60 if it holds within the price channel. Critical support is at around 5.00, 4.90, and 4.70
MSB is developing Ryoncil - an IV stem cell therapy for the treatment of acute graft versus host disease (aGVHD) in paediatrics. aGCHD is a potentially life threatening (up to 70-90% mortality) complication of bone marrow transplants (indicated for leukemia/lymphoma etc). Ryoncil has been accepted by the FDA for priority review with a PDUFA action date of US 30th...
Hello Fellow Traders!
The XJO (ASX200) has sold off from the peak made on August 25th following the SPX(US500) and Nasdaq during uncertain global times and Covid numbers starting to increase again in Europe. While the XJO continued to fall in the past 5 trading days, MSB has experienced supreme buying pressure continuing to retest $5.00.
MSB is a Bio –...
MSB has a history of using previous resistance as new support, and is likewise to do the same here, with previous 4.15 resistance to be its new support. Resistance is at 5.35.
